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Background and objective: The application of cytostatic oxazaphosphorines such as cyclo-
phosphamide (CP) and ifosfamide (IF) is associated with the risk of kidney damage that,
depending on the type of drug, dose and route of administration, adopts a different clinical
entity and severity. The aim of our study was to assess the influence of CP and IF on the kidney
histology and function in rats intraperitoneally treated with four doses of either CP or IF.
Materials and methods: A total of 30 rats were divided into three groups (10 in each group):
group 1 (control), sham treated with saline solution, group 2 (treated with 75 mg/kg b.w. of
CP), and group 3 (treated with 60 mg/kg b.w. of IF). After the treatment rats were sacrificed,
blood was collected and nephrectomy and cystectomy were performed. Qualitative and
quantitative parameters (including neutrophil gelatinase-associated lipocalin-1, NGAL-1) of
kidney function were assayed in urine and plasma.
Results: CP-treated rats were characterized by a significant polyuria, decreased urine pH and
by decreased daily urinary excretion of sodium, potassium, urea and uric acid accompanied
by increased NGAL-1 excretion. A significant decrease of the plasma uric acid concentration
was also observed. IF-treated animals were also characterized by decreased urine pH but
with normal daily urinary excretion of assessed substances (except for reduced uric acid
excretion).
Both CP and IF treated rats did not show any histopathological abnormalities in their
kidneys.
Conclusions: CP caused more advanced kidney dysfunction and some indices suggested the
development of prerenal acute kidney injury. In the CP-treated group some particularly
marked urinary and plasma uric acid disturbances suggested compensation of increased
oxidative stress as uric acid is considered to exert also antioxidant properties.
© 2017 The Lithuanian University of Health Sciences. Production and hosting by Elsevier
Sp. z o.o. This is an open access article under the CC BY-NC-ND license (http://creative-
commons.org/licenses/by-nc-nd/4.0/).
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Nephrotoxicity is defined as a structural and/or functional
kidney damage resulting from exposure to any noxious factor
of toxic or ischemic character. Drugs are one of kidney-
affecting agents, therefore the incidence of drug-induced
nephrotoxicity has been continuously increasing [1]. Some
general issues determining drug-induced kidney disease
include glomerular or tubular dysfunction, impairment of
renal blood flow or disturbances of kidney metabolic and
endocrine function, accompanied by microscopic structural
lesions or gross morphological changes [2]. The background for
nephrotoxicity are detailed pathomechanisms, affecting renal
vasculature (e.g. hemodynamic acute kidney injury or throm-
botic microangiopathy), glomeruli (e.g. minimal change
disease, focal segmental glomerulosclerosis) or tubulointer-
stitium (acute tubular necrosis, [ATN], crystal nephropathy or
tubulopathies such as Fanconi syndrome, salt wasting,
nephrogenic diabetes insipidus, syndrome of inappropriate
antidiuresis) [3,4].
Nephrotoxicity remains an important adverse drug reac-
tion (ADR) in case of administration of many classes of
pharmacological agents, including particularly: contrast me-
dia, immunosuppressants (mostly cyclosporine A), aminogly-
cosides, sulphonamides, amphotericin B, non-steroidal anti-
inflammatory drugs, gold and D-penicillamine, antihyperten-
sives, with special attention to angiotensin converting enzyme
inhibitors or diuretics [1]. Also, many cytostatic drugs are
characterized by a significant nephrotoxicity. Therefore,
despite the improvement in effectiveness of chemotherapy,
drug-induced kidney damage remains a complication entan-
gling the entire treatment [3].
Among the chemotherapeutics endowed with nephrotoxi-
city, oxazaphosphorine alkylating agents should be men-
tioned. These compounds include cyclophosphamide (CP),
ifosfamide and less frequently used trofosfamide. CP is used in
chemotherapy of both solid tumors and acute leukemia and is
used as an immunosuppressant in nonneoplastic disorders
(systemic lupus erythematosus and rheumatoid arthritis).
Ifosfamide (IF) is also an effective agent used in treatment of
solid tumors, including testicular cancer, rhabdomyosarcoma,
Wilms' tumor, Ewing's sarcoma, bone sarcomas, osteosarco-
ma and neuroblastoma as well as some forms of lymphoma
[3,5]. The main ADR of CP is hemorrhagic cystitis, induced by
acrolein – a toxic product released during CP biotransforma-
tion. Ifosfamide shares with cyclophosphamide a toxic profile
characterized by urotoxicity. Moreover, IF is considered to be
more nephrotoxic compared to CP [2,3,5]. That is due to the fact
that biotransformation of IF leads to a principal release of
chloroacetaldehyde that is attributed to exert a more powerful
nephrotoxic effect compared to acrolein [6]. To sum up,
nephrotoxicity of oxazaphosphorine agents depends on the
type of drug (CP vs. IF), the applied dose, the route of
administration, the total time of treatment, the presence of
other co-existing factors predisposing to nephrotoxicity [2,4].
That multitude of nephrotoxicity-determining factors also
results in a varied clinical description of kidney damage
evoked by use of those agents. Moreover, published reports of
kidney damage evoked by oxazaphosphorine administrationare only partial, based on the different nature of the
assessment (imaging studies, selected biochemical parame-
ters), so any more complex laboratory analysis of the issue is
still missing.
Therefore, the aim of our study was to assess the influence
of two oxazaphosphorines (CP and IF) on the renal histology
and function, estimated by panel of laboratory parameters
assessed in urine and plasma, in rats treated with four
successive doses of either CP or IF.
2. Materials and methods
The medical experiment described in this paper was approved
by the I Local Ethical Committee in Krakow. The experiment
was carried out in accordance with both the Directive 2010/63/
EU on the protection of animals used for scientific purposes
and with the Polish Act of 15 January 2015 on the protection of
animals used for scientific or educational purposes (JL,
February 26, 2015, Pos.266).
2.1. Examined groups of animals and a general plan of the
experiment
The experiment included 30 10-week-old albino Wistar rats, in
equal quantities of males and females. Animals were obtained
from the Central Animal House of the Faculty of Pharmacy of
the UJCM in Krakow.
Upon arrival to the local Animal House of the Department
of Pathophysiology of the UJCM, they were kept during the first
seven days in an isolated room in order to acclimatize to the
new living conditions. After that period, the rats were
randomly assigned to the study groups of the same size (10
in each group; 5 males and 5 females): group 1 (control rats),
group 2 (rats with CP-induced chronic cystitis), and group 3
(rats with IF-induced chronic cystitis).
All animals survived till the end of the experiment,
although the overall condition of the animals from groups
2 and 3 was deteriorating with subsequent CP/IF doses,
respectively.
During the experiment (except when rats were housed in
individual metabolic cages), animals were kept in single-sex
cages separate for the study groups, with unlimited access to
water and standard feed (Labofeed, Kcynia, Poland), in the air-
conditioned room with a constant temperature and humidity,
maintaining a 12/12-h day/night cycle.
The plan of the experiment assumed initial assessment of
vital signs, daily diuresis, feed and water consumption of all
study animals performed in individual cages. Urine samples
were collected over 24 h for subsequent laboratory analysis
and for qualitative and semi-quantitative analysis of urine
with urine dipsticks. Then, animals in groups 2 and 3 received
CP or IF treatment, respectively, to induce chronic cystitis in 7
days. Control individuals were given normal saline. After the
last CP/IF/saline dose all animals were once more monitored
during 24 h in metabolic cages, with assessment of the same
parameters as those before the treatment and urine samples
were collected again. After the second stay in metabolic cages,
blood samples for further biochemical assay were also
collected. Finally, the animals were sacrificed and cystectomy
m e d i c i n a 5 3 ( 2 0 1 7 ) 1 7 9 – 1 8 9 181and nephrectomy were performed for subsequent histopath-
ological evaluation of urinary bladders and kidneys.
2.2. Chronic cystitis induced by cyclophosphamide (group
2) or ifosfamide (group 3)
Rats in the group 2 were given CP (CP monohydrate; Sigma
Aldrich) intraperitoneally in the amount of 75 mg/kg b.w.,
dissolved in 0.5 mL of normal saline. The dose was adminis-
trated four times, every two days, after the initial monitoring
in metabolic cages on the first day of the experiment. After the
last CP dose, animals were once again placed in separate
metabolic cages. According to literature data, the approved
dosing schedule can induce chronic cystitis [7,8]. Besides
administration of CP animals were not subjected to any other
treatment.
In the group 3, the procedure was identical, but rats
received 60 mg/kg b.w. of ifosfamide. The choice of IF dose was
also based on literature reports – there are studies reporting
ifosfamide-induced nephrotoxicity in rats using 80 mg/kg b.w.
for three days [9] or 50 mg/kg b.w. for five days [10,11].
According to Springate and Van Liew [12], the recommended
urotoxic dose of IF is 40–80 mg/kg b.w. Therefore, we decided to
apply the dose of 60 mg/kg b.w. of ifosfamide as a suitable
dosage (the dosage regimen provided the same global IF dose
as in the above cited papers). Control animals (group 1) were
subjected to the same procedure as individuals of groups 1 and
2, but instead of using CP/IF, rats were sham-treated with
normal saline, in accordance with the regimen, and the
volumes used in groups 1 and 2.
2.3. Monitoring in metabolic cages
In the beginning (before receiving the first dose) and in the end
of the experiment (after the last, fourth dose of CP/IF in groups
2/3 or saline in group 1, respectively) animals were placed in
isolated metabolic cages over 24 h to measure daily urine
output and water and feed consumption. During the stay they
had a free, yet monitored access to water and food. Vital
parameters were assessed: body weight (g), body temperature
(8C), daily water intake (mL/24 h), daily food consumption (g/24 h)
and daily diuresis (mL/24 h). Body temperature was measured
using a digital rectal thermometer for rodents (Vivari, UK).
2.4. Urine dipstick control
After recording the volume of urine, samples were subjected to
general tests. Dipsticks were used for that purpose (Insight,
ACON Laboratories, REF U031-105), allowing assessment of pH
and specific gravity (SG) of urine, presence of blood, leukocytes
(white blood cells; WBC), protein, glucose, bilirubin, urobilino-
gen, ketones, nitrates. The analysis was performed strictly
according to manufacturer's guidelines.
2.5. Laboratory parameters estimated in urine and plasma
After daily urine output was measured, urine samples was
subsequently centrifuged (2000 rpm/5 min), and divided into
portions. Resulting samples were stored at 20 8C until
laboratory determinations completed with the ADVIA 1200SIEMENS analyzer. Initially, sodium, potassium, urea, creati-
nine (Cr), uric acid and protein concentrations were deter-
mined. Moreover, blood urea nitrogen (BUN) and BUN/
creatinine ratio were calculated:
BUN ¼ urea ðmg=dLÞ
2:1428
Urinary concentration (ng/mL) of novel biomarker of kidney
damage – neutrophil gelatinase-associated lipocalin-1 (NGAL-
1), using a commercially available ELISA kit (BioPorto Diag-
nostics, Denmark), strictly according to the manufacturer's
instructions, was also assessed.
Then, having results of daily diuresis, 24-h elimination of
sodium, potassium, urea (mmol/24 h), uric acid, creatinine
(mmol/24 h), protein (mg/24 h) and NGAL-1 (ng/24 h) with urine
was calculated. Creatinine clearance was also estimated,
according to the formula
CLcr ¼ Cr urine ðmmol=LÞ  diuresis ðmL=minÞCr plasma ðmmol=LÞ
Fractional sodium elimination was calculated using the for-
mula:
FENa ¼ ½ðNa urine ðmmol=LÞ  Cr plasma ðmmol=LÞÞ  100½ðNa plasma ðmmol=LÞ  Cr urine ðmmol=LÞÞ
and the renal failure index (RFI) was calculated with the
formula:
RFI ¼ ½ðNa urine ðmmol=LÞ  Cr plasma ðmmol=LÞÞ
Cr urine ðmmol=LÞ
Similarly to urine, collected blood was centrifuged and result-
ing plasma samples were kept frozen until the time of labora-
tory determinations. Plasma sodium, potassium (mmol/L) and
creatinine and uric acid (mmol/L) levels were determined using
the same analyzer as the one used for urine samples. Plasma
protein was not assayed.
2.6. Sacrificing animals and collecting kidneys and
bladders for histopathological analysis
After the second stay in metabolic cages, animals were killed
by intraperitoneal injection of a lethal dose of sodium
pentobarbital (Morbital; Biowet, Pulawy; 200 mg/kg b.w.). After
confirmed cessation of vital signs, cystectomy and nephrec-
tomy were performed in order to obtain tissue for microscopic
specimens necessary for histopathological evaluation.
2.7. Histological evaluation of collected bladders and
kidneys
Bladders and kidneys obtained during autopsy were stored in a
formalin solution until preparation of microscopic slides. The
histopathological assessment was performed at the Depart-
ment of Anatomopathology of the non-public healthcare
institution ‘‘Prosmed’’ in Krakow. The sections were cut at
preselected thickness of 4 microns using LEICA RM2135
microtome. In order to assess the severity of histological
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m e d i c i n a 5 3 ( 2 0 1 7 ) 1 7 9 – 1 8 9182inflammation, the preparations were stained with hematoxy-
lin–eosin (HE). A detailed description of the histopathological
technique is described in one of our previously published
paper [13].
2.8. Statistical analysis
Results of the quantitative analysis of urine performed with
urine dipsticks were analyzed using the nonparametric test of
signs, examining changes in the direction of the assessed
parameter, separately for each study group in the paired
comparison (pre- and posttreatment).
Results of the vital parameters and daily water and feed
intake were analyzed both for intragroup (at the beginning and
the end of the experiment) and intergroup differences,
comparing groups 1 and 2 as well as groups 1 and 3.
Differences concerning results of plasma and urine
laboratory parameters were estimated for intergroup differ-
ences, comparing groups 1 and 2 as well as groups 1 and 3.
In the statistical analysis of vital parameters and laboratory
parameters estimated in plasma or urine, in the first step, a
distribution of obtained results was analyzed using the
Shapiro–Wilk test. If results were not normally distributed,
the further analysis was performed using the Mann–Whitney
test, and if tested results demonstrated a normal distribution,
the Student t test was used. The level of statistical significance
was set at P ≤ 0.05.
3. Results
3.1. Results of vital parameters obtained from monitoring
in metabolic cages
Considering changes of the study parameters in the beginning
and in the end of the study, control animals were character-
ized by a significant increase of their body weight. The body
temperature and daily water and feed intake were comparable
throughout the experiment. Contrary to control ones, CP-
treated animals demonstrated a statistically significant
decrease of their body weight with a parallel reduction of
the amount of daily feed intake in the end of the study. Other
parameters demonstrated no statistically significant differ-
ences between the beginning and the end of the experiment.
IF-treated animals were characterized by a significant
decrease of their body temperature after the last IF dose
and, similarly to CP-treated ones, demonstrated a decreased
final 24-h feed intake. Their body weight and daily water intake
did not change over the time.
Considering intergroup differences, no significant, initial
differences were revealed between control and animals
randomized to both groups 2 and 3, thus showing lack of
differences between individuals in the beginning of the
experiment. In the end of the study, CP-treated rats differed
with respect to all parameters compared to the control ones,
whereas IF-treated animals demonstrated some significant
differences concerning their final body temperature and daily
feed intake compared to the control.
Detailed results of parameters mentioned above are
presented in Tables 1 and 2.
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m e d i c i n a 5 3 ( 2 0 1 7 ) 1 7 9 – 1 8 9 1833.2. Results of the qualitative and semi-quantitative
analysis of urine using dipsticks
Results of urine pH and SG indicated by the dipsticks test are
presented in Table 4.
In the control group, presence of blood and glucose was
demonstrated in none of urine samples in both tests, in the
beginning and in the end of the study. In the first test in that
group, leukocytes were assessed at  (15 (WBC/mL)) in 88% of
cases and at + (70 (WBC/mL)) in 12%, nitrates assessed at + in
50% and they were not detected in the remaining 50% of
samples, urobilinogen was measured at 0.2 (mg/dl) in all
samples, protein was determined at + (30 (mg/dL)) in 50% of
cases and ++ (100 (mg/dL)) in other 50%, ketones were not
found in 88% samples and were assayed at  (5 (mg/dL)) and
bilirubin was assessed at + (1 (mg/dL)) in 88% and at ++ (2 (mg/dL))
in 12%.
In the second test performed after the sham treatment with
normal saline, the findings regarding urobilinogen, protein,
blood, bilirubin and glucose were identical to the initial
assessment. The presence of leukocytes in urine decreased,
and the analysis demonstrated no leukocytes in 63% of
samples and the parameter was assessed at  (15 (WBC/mL))
in 25% and at + (70 (WBC/mL)) in 13%. In all samples nitrates
presence estimated at + was confirmed. Ketones were not
detected in 50% and in the remaining half of the samples they
were measured at  (5 (mg/dL)). Only changes in urine
leukocyte, nitrate and ketones were found to be statistically
significant.
In group 2, no blood and glucose were demonstrated in the
beginning of the study. In all samples urobilinogen was
assessed at 0.2 (mg/dL). Leukocytes were not shown in 50% of
samples and were estimated at  (15 (WBC/mL)) in 25% and at +
(70 (WBC/mL)) in 25%. The presence of nitrates was not
confirmed in 75%, and in the remaining 25% it was estimated
at +. The urine protein was measured at  (15 (mg/dL)) in 38%,
at + (30 (mg/dL)) in 12% and at ++ (100 (mg/dL)) in 50%. In
assessment of ketones, in 12% of cases they were estimated at
 (5 (mg/dL)) and other urine samples contained no ketones.
Bilirubin was assessed at + (1 (mg/dL)) in 88% and at ++ (2 (mg/
dL)) in 12%. No samples contained glucose.
In the second analysis performed in CP-treated animals, a
presence of urobilinogen assessed at + (1 (mg/dL)) and bilirubin
assessed on + (1 (mg/dL)) was found in all cases, and glucose
and ketones were absent. In 25% of samples, leukocytes were
estimated at  (15 (WBC/mL) and in 50% at + (70 (WBC/mL)) and
they were no demonstrated in 25% of samples. Nitrates marked
as + were present in 88%, whereas 12% of samples were free
from nitrates. Presence of the urinary protein was similar to the
first assessment – it was estimated at  (15 (mg/dL)) in 38%, at +
(30 (mg/dL)) in 25% and at ++ (100 (mg/dL)) in 38% of cases. There
was no blood found in half of urine samples and in 12% of them
it was estimated at + and at ++ in 38%. Considering differences
in the urine dipsticks analysis observed before and after the
treatment with CP, only changes related to the nitrates and
blood were considered to be statistically significant.
Before the IF treatment, all urine samples from rats in the
group 3 were characterized by absence of the glucose, ketones,
blood and leukocytes in 70% of cases. In 30%, leukocytes were
estimated at + (70 (WBC/mL)). Nitrates were found in 12% and
m e d i c i n a 5 3 ( 2 0 1 7 ) 1 7 9 – 1 8 9184all the other urine samples were deprived of the substance.
Urobilinogen was assessed at 0.2 (mg/dL) and bilirubin at +
(1 (mg/dL)) in all cases. Urine protein in rats in the group 3 was
not detected in 80% of cases and estimated at  (15 (mg/dL))
in 10% and at ++ (100 (mg/dL)) in 10%, before the treatment
with IF.
The IF treatment resulted in increased urine protein level of
 (15 (mg/dL)) in 90% of cases and of ++ (100 (mg/dL)) in the
remaining 10% of the cases. Moreover, in 25% of samples, blood
was also detected. All of the other parameters (leukocytes,
urobilinogen, bilirubin, ketones, nitrates, glucose) were
assessed in the same manner as in the initial assessment.
However, the performed statistical analysis indicated that the
above discussed differences were not statistically significant.
3.3. Results of the assayed plasma parameters
Administration of four doses of CP resulted both in significant
decrease of the plasma uric acid and increase in plasma
creatinine levels. However, BUN and BUN/creatinine ration did
not differ significantly in control and CP-treated animals.
Plasma sodium, urea, levels were comparable in CP-treated
and control rats.
Similarly to administration of CP, the treatment with IF
caused a significant increase in plasma creatinine level, which
was accompanied by a blood urea nitrogen value increase.
Other parameters assessed in plasma of IF-treated animals did
not differ significantly from those in control subjects.Table 3 – Plasma parameters in rats treated with cyclophosph
Control
(group 1)
CP-treated rats
(group 2)
Na, mmol/L 142.06  1.79 143.80  1.9 
Urea, mmol/L 6.34  0.75 6.76  1.07 
BUN, mg/dL 17.76  2.10 18.95  3.00 
Uric acid, mmol/L 157.96  35.14 106.1  57.56 
Creatinine, mmol/L 27.95  1.77 31.99  2.81 
BUN/creatinine, mg/dL 54.34  4.40 52.67  8.94 
Values are mean  SD. BUN, blood urea nitrogen; NS, not significant.
Table 4 – Urine parameters in rats treated with cyclophospham
Control
(group 1)
CP-treated rats
(group 2)
Diuresis, mL/24 h 5.72  1.31 11.94  4.14 
Diuresis, mL/min 0.004  0.001 0.008  0.003 
SG 1.009  0.001 1.008  0.006 
pH 9.0  0.00 8.13  1.03 
Protein, mg/24 h 5.71  4.15 3.94  2.47 
Na, mmol/24 h 0.76  0.25 0.48  0.19 
K, mmol/24 h 2.08  0.55 1.02  0.66 
Urea, mmol/24 h 5.93  1.28 4.45  1.14 
Uric acid, mmol/24 h 9.03  2.85 6.07  1.25 
Creatinine, mmol/24 h 45.56  14.14 39.38  12.52 
NGAL-1, ng/mL 1.53  0.80 3.34  2.42 
Values are mean  SD. SG, specific gravity; NGAL-1, neutrophil gelatinasDetailed results are presented in Table 3.
3.4. Results of assessed urine parameters
CP-treated rats differed in terms of the majority of estimated
urine parameters from control ones. First of all, they were
characterized by a higher value of daily diuresis (both total and
minute) with a substantial acidification of urine. CP adminis-
tration resulted also in a significant decrease in urinary
excretion of sodium, potassium, urea and uric acid. In contrast,
the daily urinary excretion of protein and creatinine was
similar in CP-treated animals and control ones.
The IF treatment resulted only in a significant decrease of
urine pH, with simultaneous increase of its specific gravity.
The daily urinary excretion of assayed substances did not
differ significantly from values of those parameters assessed
in the control group, except for the uric acid, that was –
similarly to CP-treated rats – found in the urine in diminished
amount compared to control group.
Urinary NGAL-1 concentrations were not significantly
different in all studied groups.
Detailed results are presented in Table 4.
The value of calculated creatinine clearance was similar in
both CP- and IF-treated rats (0.85  0.26 and 0.92  0.44,
respectively) and did not differ from the value found in the
control group (1.1  0.37). Moreover, animals receiving CP
demonstrated a significant decrease of calculated values of the
fractional sodium excretion and RFI compared to control rats.amide (CP) and ifosfamide (IF).
IF-treated rats
(group 3)
P
Group 1 vs. 2 Group 1 vs. 3
142.57  1.21 NS NS
7.28  1.06 NS NS
19.97  2.87 NS 0.05
189.81  94.21 0.02 NS
34.19  3.5 0.05 0.001
52.52  10.37 NS NS
ide (CP) and ifosfamide (IF).
IF-treated rats
(group 3)
P
Group 1 vs. 2 Group 1 vs. 3
8.27  5.31 0.005 NS
0.006  0.004 0.001 NS
1.013  0.006 NS 0.05
8.25  0.86 0.02 0.01
5.29  4.61 NS NS
0.63  0.37 0.04 NS
1.68  0.85 0.005 NS
5.05  2.36 0.02 NS
5.26  2.99 0.02 0.01
44.70  19.92 NS NS
1.02  0.90 NS NS
e-associated lipocalin-1; NS, not significant.
Fig. 1 – Fractional excretion of sodium (FENa) in CP-treated (left) and IF-treated (right) rats. P < 0.05 for CP-treated rats; NS, not
significant for IF-treated rats.
Fig. 2 – Renal failure index (RFI) in CP-treated (left) and IF-treated (right) rats. P < 0.05 for CP-treated rats; NS, not significant for
IF-treated rats.
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differences for abovementioned parameters of FENa and RFI
are presented in Figs. 1 and 2.
Moreover, CP-treated rats were characterized by signifi-
cantly greater 24-h urinary NGAL-1 excretion (ng/24 h)Fig. 3 – 24-h urinary excretion (ng/24 h) of neutrophil gelatinase
treated (right) rats. P < 0.05 for CP-treated rats; NS, not significancompared to control (41.44  35.32 vs. 8.64  4.36). In the
IF-treated group, daily NGAL-1 urinary excretion was similar
to the value found in the control animals (6.24  5.45 vs.
8.64  4.36). The results described above are presented in
Fig. 3.-associated lipocalin-1 (NGAL-1) in CP-treated (left) and IF-
t for IF-treated rats.
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bladders and kidneys
Specimens of urinary bladders collected from CP-treated rats
had a largely homogeneous presentation. Reactive prolifera-
tion of urothelial epithelium with multiplication of layers up to
6 and signs of dyskaryosis (nuclear polymorphism), mostly in
the basal layer of the urothelium were found in the entire
group. Moreover, an inflammatory infiltration was found in
stroma in all specimens. Kidneys in all CP-treated rats were at
the limit of a normal presentation.
Specimens of urinary bladders collected from IF-treated
animals presented an inflammatory infiltration and fibrosis of
the stroma. Kidneys of IF-treated animals appeared normal.
4. Discussion
The main findings of the study may be summarized as follows:
1. Rats treated with CP presented a significant polyuria and
acidification of urine. The administration of CP resulted also
in decreased 24-h urinary excretion of sodium, potassium,
urea and uric acid which was accompanied by a significant-
ly higher excretion of NGAL-1. Disturbances of parameters
estimated in urine were accompanied by a significant and
profound reduction of the plasma uric acid level. Moreover,
the calculated FENa and RFI had lower values in CP-treated
rats compared to control ones. An overall qualitative
assessment of urine with dipsticks also demonstrated
some more emphasized disturbances in the group of rats
treated with CP. The administration of CP was also
associated with a significant wasting of animals, reflected
by a significant reduction of their final body weight and food
intake.
2. Rats treated with ifosfamide also presented a significant
urine acidification. However, in contrast to CP-treated
animals, the 24-h urinary excretion of majority of analyzed
substances (including NGAL-1) did not differ from that
observed in the control group – rats treated with IF were
characterized only by a reduced uric acid excretion. IF
administration was also associated with increased creati-
nine and BUN plasma level, but the calculated creatinine
clearance and BUN/creatinine ratio were similar to those in
the control group. Moreover, animals treated with IF were
characterized by lesser abnormalities in the qualitative
analysis of urine compared to CP-treated rats. Also, IF
administration resulted in a much smaller cachexia
compared to rats receiving CP (no final body weight
decrease, less loss of the daily feed intake).
As already mentioned in the Introduction, ifosfamide being
the main source of chloroacetaldehyde, is regarded to be a
compound associated with a significant nephrotoxicity.
Kidneys metabolize nephrotoxic chloroacetaldehyde into a
less toxic chloroacetate and the rate of that detoxication
determines the degree of kidney damage [14]. Both oxazapho-
sphorine agents (CP and IF) are hydrophilic. For that reason
they do not easily diffuse through cell membranes and require
a presence of specific cell carriers – organic anion (OAT) andcation (OCT) transporters [15]. In the kidney, as well as in other
tissues, OAT isoforms 1 and 3 and OCT isoform 2 are located in
the basolateral membrane [16]. Both CP and IF have affinity for
OATs, but IF is preferably transported further by renal OCT-2,
which explains a greater accumulation of the compound in
kidneys and a higher nephrotoxic effect [15].
The kidney dysfunction caused by the use of IF, described in
the literature, adopts a wide spectrum, ranging from the
generalized proximal tubulopathy (Fanconi syndrome) to
partial sodium, potassium, glucose, amino acids and other
small molecule compounds' re-absorption defects [3,4,17] The
CP-induced nephrotoxicity also involves a variable tubular
dysfunction [2–5]. Moreover, the CP-induced kidney dysfunc-
tion results in reduction of tubular filtration rate and
development of an inappropriate antidiuresis syndrome [18].
Results of our study indicated an abnormal daily urinary
excretion of assessed substances by CP-treated rats (including
increased NGAL-1 excretion) and a significant urine acidifica-
tion. IF-treated animals demonstrated only an abnormally low
urine pH at urinary NGAL-1 excretion remaining at a similar
level as compared to control rats. Therefore, our study
demonstrated a significant nephrotoxicity potential for CP.
Which proves that acrolein, which is a unique compound
released during metabolic processing of CP, exerts not only
mainly urotoxic effects but also significant nephrotoxic ones.
The most likely mechanism of the acrolein-related nephro-
toxicity is complex and based on the same issues contributing
to urotoxic properties of that compound, and includes a
reduction of the kidney cellular glutathione dependent
antioxidant system and an increase in free radical generation,
mostly peroxynitrite. The compound is responsible for lipid
peroxidation – a deleterious damage of the renal tubular cells
[19]. Moreover, a significant drastic decrease (instead of an
increase) in the activities of lysosomal enzymes was observed
in kidneys of CP-treated rats. A decrease in the activities of
lysosomal protein digestive enzymes may contribute to CYP-
induced renal damage – the accumulation of abnormal
amounts of the protein in kidneys may be at least in part
due to a defect in lysosomal enzyme activity and may
contribute to renal damage [20]. To sum up, the dosage and
route of administration applied in our study showed a more
emphasized kidney dysfunction in CP-treated rats, with the
absence of any renal histopathological abnormalities. More-
over, results obtained for CP-treated animals suggest some
possible disturbances of proximal tubules (impairment of re-
absorption), as well as of distal ones (abnormal urine
acidification). It seems that IF affects only the distal nephron
function, because the agent caused only a drop of urine pH and
the analysis of NGAL-1 did not reveal any significant
abnormalities. The statement of dysfunction of distal tubules
is supported by the finding that H+ secretion into urine and,
therefore, determination of the final urine pH, takes place just
in the distal tubules [21,22]. Taking into account data
presented in Tables 1 and 2, it should be concluded that the
24-h water and food intake in both CP- and IF-treated animals
during monitoring in individual metabolic cages was almost
identical (both in the beginning and in the end of the
experiment). Therefore, in our opinion, it is unlikely that the
final pH drop observed in the treated animals resulted from
intergroup differences in water or feed consumption.
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acidification and abnormal NGAL-1 excretion, developed also
a significant polyuria, which may be considered as an
additional premise for the assumption of the distal tubule
dysfunction. Polyuria demonstrated in our study is contrary to
literature reports indicating development of the ‘‘antidiuresis
syndrome’’ after the application of CP. That disorder was due
to the increased, CP-induced expression of aquaporins via the
vasopressin-independent mechanism [23,24]. On the other
hand, however, development of IF-evoked nephrogenic dia-
betes insipidus was also reported [3]. Thus, the influence of the
oxazaphosphorine agents on diuresis is ambiguous and
requires further research, but abovementioned studies (also
including the currently discussed one) suggest disturbances
within the distal nephron due to CP/IF administration.
Taking into account all the results obtained in the group of
animals treated with CP, it is worth noting that some of them
(FENa, RFI) may suggest development of acute kidney injury
(AKI). AKI, previously referred to as acute renal failure, can be
defined as an abrupt deterioration of the all renal function
(excretory, endocrine, metabolic). In other words, it means
sudden loss of the ability of the kidneys to excrete waste,
concentrate urine, conserve electrolytes, and maintain fluid
balance [25]. AKI is conditioned by various factors of pre-, post-
or toxic/inflammatory intra-renal origin that lead to acute
kidney function decompensation [25,26]. Clinically, fractional
excretion of sodium and renal failure index are regarded
laboratory indices suggesting prerenal background of AKI
[25,27]. Low FENa is an effective marker of hypoperfusion of
the renal artery [28]. Those parameters obtained in CP-treated
rats achieved lower values compared to the control group.
Therefore, an additional assumption may be set that CP
administration also contributes to prerenal AKI features
resulting from kidney hypoperfusion, as that is the underlying
mechanism of that form of AKI [26]. The presence of polyuria
demonstrated in CP-treated rats, although is not a typical
finding, does not exclude the possibility of AKI development,
as the disorder paradoxically may be associated with polyuria
(although in the classic form is characterized by oliguria or
even anuria) [25–27].
Another evidence supporting kidney damage development
in CP-treated animals is the analysis of urinary excretion of
novel biomarker of kidney dysfunction – NGAL-1. While the
urinary concentrations of the biomarker were comparable in
all groups, the 24-h excretion of the compound was signifi-
cantly higher in CP-treated animals. NGAL-1 is a protein
synthesized and released into the plasma by many tissues:
kidneys, prostate, trachea, lung, stomach, large intestine,
uterus and bone marrow. In addition, it is released in greater
amounts from neutrophils and macrophages during inflam-
matory response and endothelial injury [29–31]. NGAL-1
exhibits pleiotropic biological properties: extracellularly, it
binds iron-complexed siderophores and regulates intracellular
metabolism of the iron, enhances the proteolytic activity of
matrix metalloproteinases (MMP-9), thereby preventing the
degradation of these enzymes by tissue MMP-9 inhibitor
(TIMP-1). This phenomenon is of particular importance in the
processes of progression of carcinogenesis [29,32]. The
augmentation of MMP-9 activity by NGAL-1 is also important
in the development of acute coronary syndromes resultingfrom atherosclerotic plaque destabilization [29,33]. Plasma
NGAL-1 level is also elevated in patients with type 2 diabetes,
thus suggesting the potential role of NGAL-1 in the pathogen-
esis of insulin resistance [34]. NGAL-1 is freely filtered in the
kidneys and reabsorbed in proximal tubules. In addition, this
protein is synthesized by Henle's lobe and distal tubules in
response to various kidney damaging factors [31,35]. There-
fore, the increased 24-h urinary excretion of NGAL-1 in CP-
treated rats could have resulted from proximal tubules failure
and reduced reabsorption of this protein and/or increased
tubular synthesis. Moreover, the hypothesis of a more potent
nephrotoxicity of CP compared to ifosfamide is also consistent
with the results of one of our other experiments. In that study,
we assessed the urinary concentration and 24-h excretion of
another novel biomarker – kidney injury molecule-1 (KIM-1).
Similar results were revealed – again, CP-treated animals were
characterized by significantly higher urinary KIM-1 concen-
tration and increased 24-h excretion of the protein with the
urine [13]. KIM-1 is a glycoprotein secreted by the proximal
tubule cells in response to any noxious factors – therefore,
plays a special role of one of the ‘‘renal troponins’’ used for
early and reliable detection of kidney injury. Under physiolog-
ical conditions, urine does not contain KIM-1 – so its presence
in the urine is regarded to be a quantitative biomarker of
kidney damage, which appears rapidly in the urine in response
to the proximal tubular damage [13].
To sum up, the increased 24-h urinary excretion of both
NGAL-1 and KIM-1 biomarkers is another proof of CP-induced
nephrotoxicity.
The next characteristic disturbance demonstrated in our
experiment was a reduced urinary excretion of uric acid that in
the case of CP-treated animals was associated with decreased
plasma level of the compound. The decrease of serum uric acid
may contribute to the development of polyuria, resulting from
abnormalities in cortico-medullary osmotic gradient and
disturbances of the countercurrent amplifier mechanism
[36,37]. The reduction of serum uric acid level (and, conse-
quently, reduced urinary excretion of the compound) may also
reflect a compensation of an excessive oxidative stress, which
is, as mentioned above, an essential, potential element of
pathomechanism of the CP-induced nephrotoxicity. Uric acid
is one of the most important, low molecular mass compounds
that is now believed to exert strong antioxidant effect [38]. In
vitro experiments demonstrated that uric acid is a powerful
scavenger of the peroxyl and hydroxyl radicals and of singlet
oxygen [39]. Moreover, uric acid is thought to be an inhibitor of
radicals generated by decomposition of peroxynitrite – a
compound also generated by the action of acrolein [40,41]. An
important premise for the antioxidant role of uric acid is the
observation that the loss of urate oxidase, resulting in
increased plasma uric acid level, improves antioxidant
defense [38]. Therefore, it can be concluded that the advanced
oxidative stress in kidneys induced by acrolein released during
biotransformation of peroxynitrite, causes secondary ‘‘ex-
haustion’’ of the compensatory antioxidant mechanisms,
including reduction of plasma uric acid level. The indirect
confirmation of the role of uric acid as an antioxidant in the
course of kidney and bladder damage is provided also by
clinical observations: a negative correlation between plasma
level of uric acid and the severity of hemorrhagic cystitis in
m e d i c i n a 5 3 ( 2 0 1 7 ) 1 7 9 – 1 8 9188children treated with CP [42]. Thus, results of our study related
to marked plasma uric acid decrease in CP-treated rats
constitute one more evidence for a role of uric acid in the
pathogenesis of kidney and bladder damage caused by CP.
5. Conclusions
To sum up, both CP and ifosfamide administrated four times
intraperitoneally caused kidney dysfunction that was more
advanced in animals treated with CP and demonstrated by
reduced 24-h excretion of sodium, potassium, urea and uric
acid, with a marked acidification of urine and increased NGAL-
1 urinary excretion. Moreover, some indices (FENa, RFI) also
suggest prerenal development of acute kidney injury.
IF-treated animals were characterized only by decreased
urine pH and reduced daily uric acid excretion.
Decreased serum uric acid levels in rats treated with CP and
decreased daily urinary excretion of the compound found in
both studied groups may reflect participation of that compound
in the antioxidant compensation phenomena that accompany
renal failure induced by oxazaphosphorine metabolites.
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